Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. This move is part of the company's strategic expansion of its contract development and manufacturing organization (CDMO) platform, which will be significantly enhanced by the planned acquisition of Recipharm Israel in the first quarter of 2026.
Kuratz brings over 30 years of leadership, supply chain, and operational experience across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee critical functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His extensive background is expected to streamline operations and support the company's growth as it integrates the new Yavne site with its existing Jerusalem operations.
The appointment follows Scinai's announcement of its expansion through the acquisition of Recipharm Israel, which adds a second development and manufacturing site in Yavne. Combined with the Jerusalem facility, the expanded platform will offer a comprehensive range of capabilities, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient (API) development and synthesis, analytical-method development, and GMP manufacturing. This integration positions Scinai to serve a broader client base in the biopharmaceutical industry.
According to the company, Kuratz's role will be pivotal in ensuring that the combined operations run efficiently and effectively, particularly as the company scales its CDMO services. His expertise in supply chain and business processes will be instrumental in harmonizing the two sites and optimizing resource utilization.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. It is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. In addition, the company owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotech and pharma companies through its facilities in Jerusalem and Yavne, Israel.
For more details on the appointment and the company's CDMO expansion, visit the press release. For the latest news and updates on Scinai Immunotherapeutics, visit the company's newsroom.
